Bank of America just raised its EUR/USD forecast
Cardlytics, Inc. (NASDAQ:CDLX) Chief Financial Officer Alexis DeSieno sold 26,048 shares of common stock on August 15, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted average price of $1.217, resulting in a total transaction value of approximately $31,700. The prices for the shares sold ranged from $1.19 to $1.265. According to InvestingPro data, the stock is currently trading near its 52-week low of $1.03, with a market capitalization of about $60 million. Analysis from InvestingPro indicates the stock is currently undervalued.
The sale was to cover tax obligations from vested Restricted Stock Units. On August 14, 2025, DeSieno also exercised options on 43,750 shares of Cardlytics common stock. InvestingPro data shows the company operates with significant debt, with a debt-to-equity ratio of 3.75. Get access to 13 additional ProTips and comprehensive financial analysis in the Pro Research Report.
In other recent news, Cardlytics Inc . reported its second-quarter 2025 earnings, revealing an earnings per share (EPS) of -$0.13, which surpassed analyst expectations of -$0.39. However, the company experienced a revenue shortfall, reporting $63.2 million compared to the anticipated $64.06 million. These recent developments highlight the mixed financial performance of the company, with better-than-expected EPS but lower-than-forecasted revenue. Despite the positive EPS surprise, concerns over declining revenues remain evident among investors. The earnings report underscores the challenges Cardlytics faces in aligning revenue with market forecasts. Analyst opinions on the company’s financial health were not disclosed in the report. There were no updates regarding mergers or acquisitions involving Cardlytics. Additionally, no analyst upgrades or downgrades were mentioned in the recent news.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.